Payment overview · 2025
General Payments
$111.57
6 reported records · 6 companies
Healthcare provider profile · identity verified
Molly J Lewandowski, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GRANDVIEW, MO · NPI 1689630154
Verified facts
What the public records show
CMS Open Payments records show Molly J Lewandowski, MD received $111.57 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.02 | 21.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.60 | 17.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.20 | 17.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.89 | 15.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.59 | 14.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.27 | 13.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.57 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 31 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 148 |
| Lisinopril | Lisinopril | 402 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 74 |
| Alendronate Sodium | Alendronate Sodium | 219 | 80 |
| Losartan Potassium | Losartan Potassium | 217 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 58 |
| Gabapentin | Gabapentin | 168 | 58 |
| Carvedilol | Carvedilol | 163 | 48 |
| Omeprazole | Omeprazole | 152 | 57 |
| Metformin Hcl | Metformin Hcl | 149 | 48 |
| Simvastatin | Simvastatin | 132 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 45 |
| Montelukast Sodium | Montelukast Sodium | 116 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 46 |
| Metformin Hcl Er | Metformin Hcl | 102 | 36 |
| Meloxicam | Meloxicam | 99 | 44 |
| Furosemide | Furosemide | 96 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 16 |
| Glimepiride | Glimepiride | 81 | 27 |
| Trazodone Hcl | Trazodone Hcl | 78 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 20 |
| Sertraline Hcl | Sertraline Hcl | 65 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 24 |
| Potassium Chloride | Potassium Chloride | 60 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 21 |
| Ezetimibe | Ezetimibe | 58 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 19 |
| Buspirone Hcl | Buspirone Hcl | 57 | 22 |
| Tramadol Hcl | Tramadol Hcl | 57 | 16 |
| Alprazolam | Alprazolam | 56 | 11 |
| Allopurinol | Allopurinol | 55 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 18 |
| Lovastatin | Lovastatin | 48 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 16 |
| Eliquis | Apixaban | 45 | 13 |
| Irbesartan | Irbesartan | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 19 |
| Ozempic | Semaglutide | 41 | 11 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Famotidine | Famotidine | 37 | 13 |
| Spironolactone | Spironolactone | 37 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Glipizide | Glipizide | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 12 |
| Gemfibrozil | Gemfibrozil | 27 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Estradiol | Estradiol | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Acyclovir | Acyclovir | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.57 · 6 records | Amgen Inc. | AREXVY, GEMTESA, KRYSTEXXA, NURTEC ODT, TRELEGY ELLIPTA, UBRELVY, WATCHMAN FLX, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error